2019 哈佛南岸计划之精神药理学规范——强迫症药物治疗流程

2019-11-28 国外精神科相关专家小组(统称) Psychiatry Res. 2019 Nov;281:112583.

强迫症的常用治疗手段包括认知行为治疗(可作为一线治疗,尤其是存在突出强迫行为者)、药物治疗及两者联用。选择性5-HT再摄取抑制剂(SSRI)为强迫症的一线治疗药物,但仅有40%-60%的患者治疗有效,进而可能需要增效治疗手段。在这一背景下,基于循证学证据制定强迫症药物治疗流程,对临床具有重要的指导意义。

中文标题:

2019 哈佛南岸计划之精神药理学规范——强迫症药物治疗流程

英文标题:

The psychopharmacology algorithm project at the Harvard South Shore Program: An algorithm for adults with obsessive-compulsive disorder

发布日期:

2019-11-28

简要介绍:

强迫症的常用治疗手段包括认知行为治疗(可作为一线治疗,尤其是存在突出强迫行为者)、药物治疗及两者联用。选择性5-HT再摄取抑制剂(SSRI)为强迫症的一线治疗药物,但仅有40%-60%的患者治疗有效,进而可能需要增效治疗手段。在这一背景下,基于循证学证据制定强迫症药物治疗流程,对临床具有重要的指导意义。

 

拓展指南:强迫症相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 哈佛南岸计划之精神药理学规范——强迫症药物治疗流程)] GetToolGuiderByIdResponse(projectId=1, id=255f31c0018a1265, title=2019 哈佛南岸计划之精神药理学规范——强迫症药物治疗流程, enTitle=The psychopharmacology algorithm project at the Harvard South Shore Program: An algorithm for adults with obsessive-compulsive disorder, guiderFrom=Psychiatry Res. 2019 Nov;281:112583., authorId=null, author=, summary=强迫症的常用治疗手段包括认知行为治疗(可作为一线治疗,尤其是存在突出强迫行为者)、药物治疗及两者联用。选择性5-HT再摄取抑制剂(SSRI)为强迫症的一线治疗药物,但仅有40%-60%的患者治疗有效,进而可能需要增效治疗手段。在这一背景下,基于循证学证据制定强迫症药物治疗流程,对临床具有重要的指导意义。 , cover=, journalId=null, articlesId=null, associationId=1320, associationName=国外精神科相关专家小组(统称), associationIntro=, copyright=0, guiderPublishedTime=Thu Nov 28 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>强迫症的常用治疗手段包括认知行为治疗(可作为一线治疗,尤其是存在突出强迫行为者)、药物治疗及两者联用。选择性5-HT再摄取抑制剂(SSRI)为强迫症的一线治疗药物,但仅有40%-60%的患者治疗有效,进而可能需要增效治疗手段。在这一背景下,基于循证学证据制定强迫症药物治疗流程,对临床具有重要的指导意义。 </P> <P> </P>拓展指南:<strong>与<font color=red>强迫症</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=3c5eb1c001e078c3" title="2019 专家共识声明:强迫症早期干预" target=_blank>2019 专家共识声明:强迫症早期干预</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=e7fab1c001e055ab" title="2019 印度临床实践指南:儿童和青少年强迫症的管理" target=_blank>2019 印度临床实践指南:儿童和青少年强迫症的管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=8233c1c001a95e55" title="中国强迫症防治指南2016 解读:概述" target=_blank>中国强迫症防治指南2016 解读:概述</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=b182b1c001a956bd" title="中国强迫症防治指南2016(精编版)" target=_blank>中国强迫症防治指南2016(精编版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=11c431c001235643" title="2016 WFSBP共识声明:焦虑症、强迫症和创伤后应激障碍的生物学标记" target=_blank>2016 WFSBP共识声明:焦虑症、强迫症和创伤后应激障碍的生物学标记</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E5%BC%BA%E8%BF%AB%E7%97%87" target=_blank>有关强迫症更多指南</a></ul>, tagList=[TagDto(tagId=10462, tagName=强迫症), TagDto(tagId=1113, tagName=药物治疗)], categoryList=[CategoryDto(categoryId=13, categoryName=精神心理科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6421, appHits=126, showAppHits=9, pcHits=2464, showPcHits=5010, likes=49, shares=2, comments=4, approvalStatus=1, publishedTime=Tue Dec 24 20:42:03 CST 2019, publishedTimeString=2019-11-28, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Dec 24 20:42:03 CST 2019, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 12:58:40 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 哈佛南岸计划之精神药理学规范——强迫症药物治疗流程)])
2019 哈佛南岸计划之精神药理学规范——强迫症药物治疗流程
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1247455, encodeId=aebd124e45500, content=别要积分呀!要积分怎么看…… , beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764c8278050, createdName=ms7000000408974145, createdTime=Tue Sep 06 13:04:21 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009270, encodeId=a1aa10092e0b6, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/3ad740e3c08446bdb16b27451fa24240/3f8741b38e3f45ab84ae3760916e347c.jpg, createdBy=60065478058, createdName=雨田X, createdTime=Wed Aug 18 21:41:52 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904466, encodeId=eeda9044662e, content=强迫症患者需要得到各界人士更进一步的关注与帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcf85440873, createdName=habit1245, createdTime=Thu Dec 03 07:44:00 CST 2020, time=2020-12-03, status=1, ipAttribution=)]
    2022-09-06 ms7000000408974145

    别要积分呀!要积分怎么看……

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1247455, encodeId=aebd124e45500, content=别要积分呀!要积分怎么看…… , beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764c8278050, createdName=ms7000000408974145, createdTime=Tue Sep 06 13:04:21 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009270, encodeId=a1aa10092e0b6, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/3ad740e3c08446bdb16b27451fa24240/3f8741b38e3f45ab84ae3760916e347c.jpg, createdBy=60065478058, createdName=雨田X, createdTime=Wed Aug 18 21:41:52 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904466, encodeId=eeda9044662e, content=强迫症患者需要得到各界人士更进一步的关注与帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcf85440873, createdName=habit1245, createdTime=Thu Dec 03 07:44:00 CST 2020, time=2020-12-03, status=1, ipAttribution=)]
    2021-08-18 雨田X

    好用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1247455, encodeId=aebd124e45500, content=别要积分呀!要积分怎么看…… , beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764c8278050, createdName=ms7000000408974145, createdTime=Tue Sep 06 13:04:21 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009270, encodeId=a1aa10092e0b6, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/3ad740e3c08446bdb16b27451fa24240/3f8741b38e3f45ab84ae3760916e347c.jpg, createdBy=60065478058, createdName=雨田X, createdTime=Wed Aug 18 21:41:52 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904466, encodeId=eeda9044662e, content=强迫症患者需要得到各界人士更进一步的关注与帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcf85440873, createdName=habit1245, createdTime=Thu Dec 03 07:44:00 CST 2020, time=2020-12-03, status=1, ipAttribution=)]
    2020-12-03 habit1245

    强迫症患者需要得到各界人士更进一步的关注与帮助

    0